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ABSTRACT
Introduction Dual point- of- care tests (POCTs) for 
detecting antibodies to HIV and syphilis have been 
developed for use with venous whole blood, serum/
plasma or finger- prick capillary whole blood. Several 
tests are commercially available showing encouraging 
performance compared with ‘gold- standard’ reference 
tests in laboratory- based studies. However, data on their 
performance in the field are limited. This prospective 
cross- sectional study will conduct a clinic- based 
evaluation to assess the performance characteristics 
and acceptability to end- users of two dual HIV/syphilis 
POCTs for the screening of HIV and syphilis among men 
who have sex with men (MSM), sex workers (SWs) and 
pregnant women (PW). This master protocol outlines 
the overall research approach that will be used in seven 
countries.
Method and analysis MSM, SWs and PW presenting 
at clinic evaluation sites in high, low and middle- income 
countries will be enrolled. The (WHO preapproved) POCTs 
to be evaluated are SD Bioline HIV/Syphilis Duo (Abbott) 
and Dual Path Platform HIV- Syphilis Assay (Chembio). 
Finger- prick blood will be collected to perform POCTs and 
compared with laboratory results (venepuncture blood). 
Procedures will be carried out by trained healthcare staff 
and tests performed according to the manufacturers’ 
directions. Sample size was calculated based on local 
prevalence of HIV and syphilis. The sensitivity, specificity, 
positive and negative predictive values for each POCT 
will be calculated. The study is ongoing with recruitment 
expected to be completed in all countries by mid to late 
2021.
Ethics and dissemination This core protocol was 
independently peer reviewed and approved by the 
Research Project Review Panel (RP2) of the WHO 
Department of Sexual and Reproductive Health and 
Research and by the WHO Ethics Review Committee (ERC). 
The protocol has been adapted to individual countries 
and approved by RP2, ERC and institutional review boards 
at each site. Results will be disseminated through peer- 
reviewed journals and relevant conferences.
INTRODUCTION
Serological tests are the diagnostic tests of 
choice for both syphilis and HIV. For syphilis, 
two serological tests (treponemal and non- 
treponemal) are used for laboratory diag-
nosis. Traditionally, a non- treponemal assay is 
used for screening and a specific treponemal 
assay is then used for confirmation. However, 
with increasing automation and decreasing 
cost, some institutions use the ‘reverse’ algo-
rithm, whereby initial screening is performed 
with automated treponemal enzyme- linked or 
chemiluminescence immunoassays. If reactive, 
Strengths and limitations of this study
 ► To our knowledge, the study is the first independent 
multicentre and multicountry clinic- based evalua-
tion of dual HIV/syphilis point- of- care tests (POCTs) 
for the screening of men who have sex with men, 
sex workers and pregnant women.
 ► The clinic- based evaluation protocol design more 
accurately reflects real- world conditions and there-
fore has greater potential to demonstrate the dual 
POCTs’ practical value as a screening tool, com-
pared with laboratory- based evaluations.
 ► Although dual HIV/syphilis POCTs can be convenient 
for patients, treponemal antibodies persist following 
successful treatment of syphilis. Therefore, addition-
al treponemal and non- treponemal tests may still be 
required for correctly identifying active infections.
 ► The public health significance of this study is based 
on the premise that it will evaluate the performance 
characteristics of two dual POCTs in field settings 
as well as enable assessment of operational char-
acteristics by healthcare workers and acceptability 
to patients.
 ► The study will identify opportunities to support the 
WHO Global Health Sector Strategy on Sexually 
Transmitted Infections, 2016–2021.
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it is followed by a second manual non- treponemal test such 
as the rapid plasma reagin (RPR) assay to assess disease 
activity.1
With respect to HIV diagnosis, two different rapid 
lateral flow immunochromatographic assays or auto-
mated enzyme immunoassays (EIAs) are used in tandem 
for screening and confirmation. In some settings, a 
western blot assay is performed for the confirmation of 
a positive result. However, some of these tests are techni-
cally demanding and require laboratory equipment that 
is not always widely available in resource- limited settings. 
Therefore, in recent years, there has been consider-
able effort to develop new diagnostic tools including 
point- of- care tests (POCTs), which can be used outside 
of a typical clinical laboratory (eg, a physician’s office, 
hospital bedside, patient’s home, in the field/community 
based), by non- laboratory trained healthcare providers 
(HCPs).2 Over the last decade, many POCTs for sexually 
transmitted infections (STIs) have been developed and 
are commercially available.3 Guidance or recommenda-
tions regarding the placement of these new tests in the 
diagnostic pathway for STIs are limited, however, interim 
recommendations on the use of POCTs among pregnant 
women (PW) are available.4 Furthermore, although vali-
dated and licensed rapid HIV assays are commercially 
available and widely used in the field, they are standalone 
and do not offer the function of dual screening. As a 
result, syphilis testing coverage may be suboptimal rela-
tive to HIV. Integrated testing services will improve testing 
coverage.5 6 The WHO Global Health Sector Strategy on 
STIs acknowledges the lack of reliable, low- cost POCTs as 
a major barrier to advancing STI control and prevention.7
As HIV and syphilis can be asymptomatic, sensitive diag-
nostic testing is crucial for early detection and diagnosis and 
for the guidance of treatment and prevention of onward 
transmission.8 Dual tests that can be used at the point- of- 
care for simultaneously detecting antibodies to HIV and 
syphilis (dual HIV/syphilis POCTs) have been developed 
for use with finger- prick capillary whole blood. To date, 
they have shown encouraging performance compared with 
‘gold- standard’ diagnostic reference tests in laboratory- 
based studies; but there are limited data on their perfor-
mance in the field.9 10 Field studies in real- world settings are 
important because the performance of POCTs, including 
positive predictive values (PPVs) and negative predictive 
values (NPVs), can be influenced by epidemiological and 
environmental factors. Both operational characteristics 
of the test and human factors, such as the ability to follow 
properly the POCT procedures (eg, taking whole blood 
finger- prick specimens, correct timing of adding the buffer 
and reading the result and interpreting results accurately), 
can interfere with the performance of a POCT.11 Evalua-
tion of the performance of these dual tests in clinic- based 
settings and their acceptability to patients and HCPs is 
therefore a high priority. The need for standardised high- 
quality evaluations of POCTs was identified by two WHO 
technical consultations as being critical for the develop-
ment and global uptake of POCTs for STIs.7
Consequently, the Sexual and Reproductive Health 
and Research Department of WHO has established the 
global ProSPeRo study (Project on Sexually Transmitted 
Infection Point- of- careTesting). The overall objectives 
are to (1) advise WHO Member States and other public 
health institutions on the performance characteristics of 
commercially available STI diagnostic tests that can be 
used at the point- of- care, (2) assess the feasibility, accept-
ability of POCTs by both HCPs and clients/patients and 
(3) support further implementation and rollout of STI 
POCTs within national STI programmes by the provision 
of technical assistance tools.
ProSPeRo comprises three core components: (1) a 
laboratory- based arm assessing the performance charac-
teristics of STI POCTs that have not yet been evaluated 
independently in the laboratory12 (2) a clinic- based 
component to evaluate STIs POCT performance in the 
field compared with that of gold- standard laboratory tests 
among several STI high- risk and vulnerable populations 
worldwide and (3) a clinical utility component assessing 
the feasibility and acceptability of STI POCTs among men 
who have sex with men (MSM) in non- clinical settings in 
four countries within the WHO European region.
This master protocol refers to the second component 
of ProSPeRo, a clinic- based evaluation of dual POCTs for 
the screening of HIV and syphilis in MSM, sex workers 
(SW) and PW. These groups were identified as those 
most in need of increased access to testing based on a 
series of consultations led by WHO, which considered 
definitions of key and vulnerable populations13 and the 
epidemic trends of HIV/STIs among them.14 15 Further-
more, elimination of mother- to- child- transmission of 
syphilis and HIV is considered to be one of the most cost- 
effective public health interventions and WHO guidance 
for country- level action includes targets for the screening 
and treatment of PW.16
A clinic- based evaluation is used to determine test 
performance when the test is performed by clinic 
personnel who are not trained laboratory technicians. 
This paper outlines the master protocol within ProSPeRo, 
describing the overall research approach that will be 
used for a clinic- based evaluation of dual POCTs for the 
screening of HIV and syphilis in MSM, SW and PW. The 
protocol was developed using the QUADAS-2 framework, 
a Quality Assessment tool for primary Diagnostic Accu-
racy Studies.17 The protocol will be adapted accordingly 
for individual countries taking part.
Objectives
The primary objectives of this clinic- based evaluation are 
to assess: (1) the performance of two dual POCTs for the 
screening of HIV and syphilis in MSM, SW and PW using 
finger- prick capillary whole blood compared with refer-
ence laboratory- based serum tests for HIV and syphilis 
(HIV 1/2 EIA and the treponemal reference test) and (2) 
the minimal operational characteristics and acceptability 
of these dual HIV–syphilis POCTs to both patients and 
HCPs. A secondary objective is to explore the performance 
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and the potential utility of these dual HIV–syphilis POCTs 
in identifying active syphilis using a combination of non- 
treponemal and treponemal tests as a comparator.
METHODS AND ANALYSIS
Study setting and design
This clinic- based evaluation is a multisite, observational, 
cross- sectional study of MSM, SW and PW presenting at 
sexual health and antenatal clinics for HIV/STI screening 
according to national guidelines. The study will be imple-
mented across multiple countries and in some countries, at 
multiple sites, on the basis of locally adapted protocols. For 
the purposes of this protocol, the term study site or eval-
uation site refers to an individual clinic (sexual health or 
antenatal).
This paper is the master protocol and outlines the 
overall research approach that will be adapted accord-
ingly for individual countries. Seven international sites 
have been approved by WHO in consultation with 
in- country researchers and providers as well as local 
authorities and WHO Country Offices (Italy, UK, Malta, 
Peru, Uganda, Morocco, South Africa). A standardised 
site assessment is implemented as part of the approval 
process for sites expressing an interest to participate. 
Site- specific protocols are developed with WHO and the 
in- country principal investigator to agree and delineate 
the range of parameters and the minor changes needed 
to adapt the study to the local context while complying 
with this master protocol. The study is ongoing with 
recruitment expected to be completed in all countries by 
mid to late 2021.
Study participants
Inclusion criteria
The target populations are MSM, SW and PW. The term 
MSM is used to describe those men who have sex with 
other men, regardless of whether or not they have sex 
with women or have a personal or social identity associ-
ated with that behaviour, such as being ‘gay’ or ‘bisexual’. 
Sex work is the provision of sexual services for money or 
goods. SWs are women/men who receive money or goods 
in exchange for sexual services and who consciously 
define those activities as income- generating even if they 
do not consider sex work as their occupation. Antibiotic 
usage in participants who have been prescribed treatment 
for syphilis or other infections 3 weeks prior to study entry 
will be recorded in the data collection form but not used 
as a criterion for exclusion. All participants have to be at 
least 18 years old to participate.
Healthcare staff who administer the POCTs will also be 
asked to complete a short questionnaire to evaluate the 
operational characteristics (box 1). In order to be eligible 
to complete this, they need to have been trained in and 
administered the POCTs and give consent to complete the 
questionnaire.
Exclusion criteria
MSM, SW, PW, and healthcare staff who refuse to give 
consent, are younger than 18 years and/or have previ-
ously participated in the study.
Description of the POCTs under evaluation
The tests to be evaluated are SD Bioline HIV/Syphilis 
Duo (Abbott Diagnostics, USA; hereafter termed Bioline 
POCT) and Chembio Dual Path Platform (DPP) HIV–
Syphilis Assay (Chembio, USA; hereafter termed Chembio 
POCT). Both are single- use qualitative immunochro-
matographic assays for the simultaneous detection of HIV 
and syphilis (treponemal component) in human serum, 
plasma, whole venous or fingerpicked blood. The Bioline 
POCT (figure 1) detects antibodies of all isotypes (IgG, 
IgM, IgA) against HIV specific antigens (HIV-1 gp41, 
sub O, HIV-2 gp36) and specific IgG and IgM antibodies 
against a 17 kDa recombinant Treponema pallidum antigen 
(rTp17 kDa). In 2015, this test was accepted for the WHO 
list of prequalified in vitro diagnostics.18 The Chembio 
POCT detects specific antibodies against HIV types 1 and 
2 (HIV 1/2) and Treponema pallidum (figure 2). Recently, 
the Chembio company developed the DPP Micro Reader 
(MR) to complete the Chembio DPP technology and 
minimise error due to subjective visual interpretation 
(figure 3). The MR is a portable battery- powered cubic 
reflectance reader with a liquid crystal display. The 
display shows the status of the instrument and test result 
to the operator and a multifunction button on top turns 
on the MR and guides the operator. The device is fitted to 
the Chembio POCT via a dedicated holder. The MR scans 
Box 1 Acceptability questions and operational 
characteristics
Healthcare staff—operational characteristics
1. Clarity of kit instructions (difficult to follow, fairly clear, very clear, 
excellent).
2. Ease of use (complicated, fairly easy, very easy, excellent).
3. Ease of interpretation of results (difficult, fairly easy, very easy, 
unambiguous).
4. Rapidity of test results (<20 min, 20–30 min, >30 min).
5. Hands on time (<5 min, 5 min, 10 min, >10 min).
6. Training time required (<30 min, 30 min, 1 hour, >1 hour)
7. Number of tests needed to be performed before being able to feel 
comfortable administering a point- of- care test.
8. Overall comment/recommendation (free text response).
Patient—acceptability questions
1. Would you be willing to wait for the results at the clinic, directly after 
the tests are performed? (yes, no, do not know).
2. If yes, how long would you be willing to wait? (up to 20 min, up to 30 
min, up to 1 hour, up to 2 hours, do not know, other).
2.1. If other, please describe.
3. Would you prefer two single tests or one dual test? (single, dual, it’s 
the same, do not know/don’t care).
3.1. If you prefer a single test, why? (do not want to be tested for HIV, 
do not want to be tested for syphilis, other).
3.1.1. If other, please describe.
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the Chembio POCT cartridge and verifies the presence 
of line(s) at the control and each of the test line positions 
and measures numerically the optical density of each test 
line(s). The device interprets the results comparing the 
optical density with that of a scoring algorithm and trans-
lating it into a numerical value. This number is compared 
with that of the set cut- off (>20 for the HIV component, 
>10 for the treponemal component) and if higher, the 
POCT result is displayed as reactive (R), otherwise, as non- 
reactive(NR). If the MR reading phase is not successful, 
the displayed result is invalid (I).
Reference laboratory tests
For this master protocol, Bioline and Chembio POCTs 
HIV/syphilis results will be compared with those of the 
reference or ‘gold- standard’ tests for this evaluation; 
respectively these are laboratory- based HIV 1/2 EIA 
confirmed by immunoblot (antibody only), and for 
syphilis, the reference test is the Treponema Pallidum 
Particle Agglutination (TPPA). All reference tests will 
be performed in accordance with the manufacturer’s 
directions and laboratory staff will be blinded to the 
POCT results. For the determination of potential utility, 
a probable active syphilis case is defined as non- Tp (such 
as RPR test positive at a titre >8), confirmed by TPPA.
Acceptability of dual POCTs
The acceptability of the dual POCTs to patients will be 
determined as part of the evaluation using a structured 
questionnaire. Moreover, at the end of enrolment, 
operational characteristics will be evaluated by health-
care staff who administer the POCTs via a brief self- 
completion provider questionnaire. These acceptability 
questions and operational characteristics are displayed 
in box 1.
Study procedure
Recruitment, enrolment and consent
For each site, patients will be recruited over 9 months 
(maximum) or until the required sample size is reached. 
Consecutive MSM, SW and PW presenting to the clinic 
for HIV/STI screening at the evaluation sites will be 
informed about the study by HCP 1 (see figure 4 patient 
flowchart). If they are interested in participating (precon-
sent), a second HCP (HCP 2) will evaluate the inclusion 
criteria and provide a participant information sheet and 
informed consent form. If the potential participant fits 
the criteria and agrees to participate, HCP 2 will take final 
written informed consent and HCP 3 will perform the 
routine care (below) and the additional tests along with 
completion of the associated case report forms (CRFs).
Specimen collection
The HCP will undertake a routine examination of the 
patient according to local clinical procedures. Partici-
pants will be asked to complete an acceptability question-
naire. About 3–5 mL of venous blood will be collected 
for reference testing and placed into labelled collection 
tubes (with anticoagulant that does not interfere with the 
assays) and then transported to the laboratory in accor-
dance with standard operating procedures at the local 
site. The venous blood sample will be processed for refer-
ence testing within 12 hours of collection or centrifuged 
and stored at 2°C–8°C for 5 days maximum.
A capillary whole blood sample will be collected using 
finger- prick blood to perform both POCTs according to 
the manufacturers’ instructions, collecting the required 
amount of capillary blood using the equipment provided 
in both test kits and waiting a determined time (measured 
with a timer for each test) before reading the results. With 
the finger only being pricked once, the first blood drop 
will be used for the Bioline test and the second drop for 
the Chembio test. A double reader method (reader 1–
reader 2 (R1–R2)) will be adopted for both tests to deter-
mine any variability in the interpretation of test results.11 
The MR (Chembio) will be read by R2 only. R1 and R2 
will be blind to each other’s results and to the clinical 
history of the patients.
Follow-up procedure
Pretest and post- test counselling will be provided to all 
participants according to WHO recommendations and 
Figure 1 Bioline point- of- care test.
Figure 2 Chembio point- of- care test kit. DPP, Dual Path 
Platform.
Figure 3 Chembio DPP micro reader. DPP, Dual Path 
Platform; RFID, Radio- Frequency IDentification.
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local clinical practice. Participants will not be informed 
of their POCT results and the results will not be used 
for follow- up because the POCTs are being evaluated in 
the context of already established clinical testing proce-
dures. Patients with a positive reference test result will be 
treated according to the standards of care described in 
the national guidelines for each evaluation site.
Outcomes
Primary outcome: the primary outcome is a measure of 
the performance of two dual POCTs for the screening of 
HIV and syphilis. Each test component will be considered 
separately and compared with the respective gold stan-
dard. Readings of the first rater (R1) will be considered 
as the outcome variable for the comparison. Secondary 
outcomes: two secondary outcomes are as follows: (1) 
the acceptability of the two dual HIV/syphilis POCTs to 
patients and HCPs and (2) the potential utility of two dual 
HIV/syphilis POCTs in identifying active syphilis using a 
combination of non- treponemal and treponemal tests.
Sample size
The formula used for the sample size calculation is 
based on the 2006 WHO/TDR (Special Programme for 
Research and Training in Tropical Diseases) expert panel 
document on the evaluation of new diagnostic methods 
and techniques.19 As per the standard approach, the 
sample size is adjusted for the infection prevalence using 
the formula (100/prevalence × sample size using sensi-
tivity/specificity only). For example, if it is estimated that 
the sensitivity of a new test is 80% compared with the 
reference standard, then 200 infected study subjects by 
the reference standard test would need to be recruited 
for a CI of +5% around the point estimates of sensitivity 
and specificity. If the prevalence of infection in the study 
population is 10%, then there will be 10 infected subjects 
per 100 healthcare users seen at the clinic. Then 2000 
(100/10×200) participants will need to be recruited.
Project and data management
To ensure appropriate implementation of this master 
protocol, the following actions will be conducted: (1) 
development of site- specific study management plans 
including details of the roles and responsibilities of the 
study/evaluation team (the composition and number 
of study team members will be adapted at each site 
according to local need), (2) WHO monitoring visits 
and monitoring procedures to assess the progress and 
quality of the study at each evaluation site, (3) an external 
quality assurance process to standardise reference testing 
results from different sites by use of proficiency panels 
sent by the Centres for Disease Prevention and Control in 
the USA (a WHO reference laboratory), (4) an internal 
(serum) and external (dried tube specimens) quality 
assurance process for ensuring accurate performance of 
the dual HIV/syphilis POC tests and (5) a site- sensitive 
training programme for all clinic staff in specimen collec-
tion and handling including performance and reading of 
the POCTs as well as familiarisation with the study stan-
dard operating procedures.
All data generated will be recorded using WHO stan-
dardised CRFs. Paper versions will be stored securely 
at each study site as per local standard procedures. At 
regular intervals, data from these CRFs will be entered by 
a data manager at each site into a WHO provided secured 
laptop using OpenClinica software. Once data entry 
is complete, local data managers will be requested to 
re- enter a random allocation of data to reduce data entry 
error. Once both enrolment and data entry are complete, 
the dataset will be deidentified. Archiving (including 
destruction) of paper versions of the CRFs will be deter-
mined by the evaluation sites’ own procedures.
Data analysis
Data analysis will be guided by QUADAS-2 principles.17 
Sensitivity, specificity, PPVs, NPVs, likelihood ratio of 
a positive test and likelihood ratio of a negative test for 
each rapid test component will be estimated comparing 
the POCT results with the gold- standard laboratory test 
results. Each rapid test component will be then compared 
with the respective gold standard, namely, POCT trepo-
nemal versus laboratory- based treponemal (TPPA) for 
syphilis and POCT HIV result versus laboratory- based 
HIV EIA and/or immunoblot. 95% CIs of each estimate 
will be calculated.
To validate the reading of the POCT outcome variable, 
the concordance between the R1–R2 readings will be 
estimated by calculating percentage agreement (concor-
dance) and Cohen’s kappa (κ for binary variables).
Cohen’s κ represents a measure of inter- rater agree-
ment, ranging from −1 to +1, where 0 is the level of agree-
ment that can be expected in case of random chance.
Patient and public involvement
Patients, representatives of communities, and health-
care staff were consulted during the development of this 
master protocol specifically regarding participant recruit-
ment and approach. Additional consultations were held 
during adaptation of the master protocol to individual 
sites.
ETHICS AND DISSEMINATION
This master protocol was independently peer reviewed 
and approved by the Research Project Review Panel 
(RP2) of the WHO Department of Sexual and Reproduc-
tive Health and Research and by the WHO Ethics Review 
Committee (ERC). It has also been adapted to individual 
countries and approved by RP2, ERC and institutional 
review boards at each site (see online supplemental file). 
As the study’s procedures generally follow standard of care 
pathways at each clinic site, minimal risks are foreseen. 
However, one potential risk identified by the WHO ERC 
was the recruitment of participants from key populations, 
particularly MSM, in countries where self- identification as 
MSM could cause harm for study participants. Therefore, 
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sites will only be included in the study if they have experi-
ence of working with key populations, which is reviewed 
as part of the initial site- assessment. Some patients might 
experience a small amount of transient discomfort when 
the finger- prick blood sample is taken for use with the two 
POCTs. All data and records are to be used only for the 
purpose of the research project. Names will not be used 
on any study form or label on laboratory specimens or in 
any report resulting from the study. At the beginning of 
the study, a unique study identification number will be 
assigned to each participant. This number will be used to 
link the different types of data collected for each partici-
pant (demographic and behavioural information, biolog-
ical samples) and their POCT and reference test results.
All information/data obtained will be kept confiden-
tial. Only members of the clinic study team (HCPs) will 
have access to information linking a name with a study 
number. All participants will provide written informed 
consent and may withdraw from the study at any time 
without affecting the medical care they receive from the 
clinical team. There will be no immediate benefits to 
research participants by taking part in the study. However, 
when the study results are known and if the POCTs are 
found to be acceptable in terms of accuracy, patients may 
benefit from being able to access a validated dual POCT 
available to screen simultaneously for HIV and syphilis 
and receive treatment if indicated.
Evaluation results will be published in a WHO report 
for member states and posted on the WHO website. Local 
and global findings of the HIV/syphilis POCT validation 
study will be presented during national/international 
scientific meetings and will be published in peer- reviewed 
international journals. A further accessible community 
report will be developed for participants interested in the 
study and other interested parties.
DISCUSSION
There has been rapid development during the last decade 
to develop new diagnostic tools that can be administered 
at the point- of- care and that are Affordable, Sensitive, 
Specific, User- friendly, Rapid, Equipment- free, and Deliv-
erable (ASSURED).20 21 To date, a rich pipeline of prom-
ising diagnostic products is emerging although some 
products are stalled early in the development process, 
and few have been evaluated robustly in real- life settings. 
This has arguably not only led to a lag in the integrated 
scale- up of POCTs in public health strategic planning but 
also meant that there is still no formal WHO guidance 
and recommendations available regarding the placement 
of these new tools in the diagnostic pathway of HIV/STIs.
This paper describes the master protocol of the ProS-
PeRo study, to conduct a clinic- based evaluation assessing 
the performance and acceptability of two dual POCTs 
for the screening of HIV and syphilis in MSM, SW and 
PW. The study will offer a potentially important contribu-
tion to the WHO Global Health Sector Strategy on STIs 
(2016–2021) as well as the Sustainable Development Goals 
(particularly goal 3). Specifically, the ProSPeRo findings 
and publications (expected from 2022) will contribute to 
the evidence needed to develop the guidance for WHO 
Member States and other relevant public health institu-
tions on STI diagnostic tests that can be used at the point- 
of- care. The study will also contribute to the development 
of a high- quality standardised evaluation approach for 
POCTs in laboratory and real- world settings. A robust 
evidence- based framework has been highlighted as a 
priority for the advancement of development and global 
uptake of POCTs for STIs.7 Longer term, the findings of 
ProSPeRo may contribute to a gradual shift towards the 
decentralisation of health systems as STI POCTs within 
national STI programmes are implemented further 
and scaled up. Such decentralisation can have consid-
erable advantages regarding accessibility of services and 
follow- up as well as relieving pressures on overstretched 
health systems, particularly in terms of personnel, infra-
structure and ensuring quality of service.
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